

Exploring Current Patterns of Care in the Community: Optimizing the Use of Oral Selective Estrogen Receptor Degraders for HR-Positive Metastatic Breast Cancer, Part 2

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The FDA has granted approval to which of the following oral selective estrogen receptor degraders (SERDs) as monotherapy for patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations who experienced disease progression after at least 1 line of endocrine therapy?
 - a. Camizestrant
 - b. Elacestrant
 - c. Giredestrant
 - d. Imlunestrant
 - e. Both a and c
 - f. Both b and d
2. Which of the following outcomes best describes progression-free survival (PFS) results from the Phase III EMBER-3 trial comparing imlunestrant and abemaciclib to imlunestrant monotherapy?
 - a. Significant improvement with imlunestrant and abemaciclib among patients with ESR1 mutations
 - b. Significant improvement with imlunestrant and abemaciclib among all patients regardless of ESR1 mutation status
 - c. Improvement with imlunestrant monotherapy across all patient subgroups
3. Which of the following adverse events is most frequently observed with imlunestrant?
 - a. Hypertriglyceridemia
 - b. Photopsia
 - c. Diarrhea
 - d. Bradycardia
4. The Phase III evERA trial demonstrated which PFS outcome with the combination of giredestrant and everolimus compared to standard endocrine therapy and everolimus for patients with previously treated ER-positive, HER2-negative advanced breast cancer?
 - a. The combination led to a statistically significant improvement in PFS only for patients with ESR1 mutations
 - b. The combination led to a statistically significant improvement in PFS for patients in the intention-to-treat (ITT) population and for those with ESR1 mutations
 - c. The combination did not lead to a statistically significant improvement in PFS for patients in the ITT population or for those with ESR1 mutations
5. Photopsia has been reported as a side effect with which of the following oral SERDs?
 - a. Elacestrant
 - b. Camizestrant
 - c. Imlunestrant
 - d. Giredestrant